Heron Therapeutics, Inc.

HRTXNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
0.36 USD
↗ 0.01 (2.70%)🟢PRE MARKET (AS OF 07:16 AM EDT)
🟢Market: OPEN

Heron Therapeutics, Inc. (HRTX) trades at $0.36 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, HRTX trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Oct 2, 2026.

Open?$0.37
High?$0.37
Low?$0.36
Prev. Close?$0.35
Volume?3.6K
Avg. Volume?2.3M
VWAP?$0.36
Rel. Volume?0.00x
Bid / Ask
Bid?$0.30 × 100
Ask?$0.44 × 100
Spread?$0.14
Midpoint?$0.37
Valuation & Ratios
Market Cap?66.4M
Shares Out?189.9M
Float?143.2M
Float %?75.4%
P/E Ratio?N/A
P/B Ratio?9.62
EPS?-$0.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Themes
Biotech - Drug Development›Clinical-Stage Platforms
Employees
128
Market Cap
66.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.herontx.com
Listed
1987-08-27
Address
4242 CAMPUS POINT COURT, SUITE 200
SAN DIEGO, CA 92121
Phone: (858) 251-4400
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
48
Short Sent.?
10
Piotroski F-Score?1/9Weak
Altman Z-Score?-9.57Distress
Confidence?59%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?30.30%Squeeze Risk
Short Interest?43.4M
Days to Cover?27.8
Free Float143.2M
Avg Daily Volume1.6M
Settlement Date2026-09-15
Financial Health
Current Ratio?2.49Strong
Quick Ratio?1.51Adequate
Cash Ratio?0.22Low
Debt/Equity?20.65High
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
20
9.62HIGH▾
P/S?
Peers
100
S&P
97
0.44CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-21.6CHEAP▾
EV/Sales?
Peers
100
S&P
88
1.25CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-492.9%WEAK▾
ROA?
S&P
3
-13.5%WEAK▾
Cash Flow & Enterprise
FCF?$-12135000
Enterprise Value?$188.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist